CSL Limited
CMXHFOTCHealthcare● Active
$70.66
+$0.12(+0.17%)
Market Cap$33.8B
P/E Ratio—
52W High$184.09
52W Low$63.99
CSL Limited (CMXHF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CMXHF · earnings · updated Jun 9, 2026
Latest Earnings
Q1 FY2026Report Date: Feb 10, 2026EPS Actual
$4.03
Est. $4.14 · -2.7%
Revenue
$8.33B
Est. $8.51B · -2.0%
Fiscal Period
Q1 FY2026
FY ends December
Report Date
Feb 10, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
CMXHF reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 18, 2026 | $2.23 | — | — | — | $7.12B | — |
| ▼ Q1 FY2026 | Feb 10, 2026 | $4.14 | $4.03 | -2.7% | $8.33B | $8.51B | -2.0% |
| ▼ Q3 FY2025 | Aug 18, 2025 | $2.62 | $1.38 | -47.3% | $4.74B | $7.18B | -34.0% |
| ▼ Q1 FY2025 | Feb 11, 2025 | $4.41 | $2.56 | -42.0% | $5.08B | $8.54B | -40.5% |
| ▲ Q3 FY2024 | Aug 13, 2024 | $1.80 | $1.83 | +1.7% | $4.50B | $6.63B | -32.1% |
| ▼ Q2 FY2024 | Apr 11, 2024 | $4.07 | $2.78 | -31.7% | $5.69B | $7.94B | -28.3% |
| ▼ Q2 FY2023 | Jun 30, 2023 | $1.67 | $0.82 | -51.1% | $3.94B | $6.16B | -36.0% |
| ▼ Q4 FY2022 | Dec 30, 2022 | $3.50 | $2.36 | -32.6% | $4.97B | $6.90B | -27.9% |
Q3 FY2026
Aug 18, 2026
EPS Actual
—
EPS Est.
$2.23
EPS Surpr.
—
Revenue
—
Q1 FY2026
Feb 10, 2026Miss
EPS Actual
$4.03
EPS Est.
$4.14
EPS Surpr.
-2.7%
Revenue
$8.33B
Q3 FY2025
Aug 18, 2025Miss
EPS Actual
$1.38
EPS Est.
$2.62
EPS Surpr.
-47.3%
Revenue
$4.74B
Q1 FY2025
Feb 11, 2025Miss
EPS Actual
$2.56
EPS Est.
$4.41
EPS Surpr.
-42.0%
Revenue
$5.08B
Q3 FY2024
Aug 13, 2024Beat
EPS Actual
$1.83
EPS Est.
$1.80
EPS Surpr.
+1.7%
Revenue
$4.50B
Q2 FY2024
Apr 11, 2024Miss
EPS Actual
$2.78
EPS Est.
$4.07
EPS Surpr.
-31.7%
Revenue
$5.69B
Q2 FY2023
Jun 30, 2023Miss
EPS Actual
$0.82
EPS Est.
$1.67
EPS Surpr.
-51.1%
Revenue
$3.94B
Q4 FY2022
Dec 30, 2022Miss
EPS Actual
$2.36
EPS Est.
$3.50
EPS Surpr.
-32.6%
Revenue
$4.97B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $4.20 | $4.20 | $4.20 | 1 |
| Q3 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
| Q2 FY2025 | $2.62 | $2.62 | $2.62 | 1 |
| Q4 FY2024 | $4.51 | $4.51 | $4.51 | 1 |
| Q2 FY2024 | $1.80 | $1.80 | $1.80 | 1 |
| Q4 FY2023 | $4.14 | $4.14 | $4.14 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $8.5B | $8.5B | $8.5B | 1 |
| Q3 FY2025 | $7.4B | $7.4B | $7.4B | 1 |
| Q2 FY2025 | $7.2B | $7.2B | $7.2B | 1 |
| Q4 FY2024 | $8.5B | $8.5B | $8.5B | 1 |
| Q2 FY2024 | $6.6B | $6.6B | $6.6B | 1 |
| Q4 FY2023 | $8.0B | $8.0B | $8.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q1 FY2026 | Feb 10, 2026 | -2.7% | $121.74 | $125.60 | +3.17% |
| ▼ Q3 FY2025 | Aug 18, 2025 | -47.3% | $168.35 | $179.00 | +6.33% |
| ▼ Q1 FY2025 | Feb 11, 2025 | -42.0% | $169.50 | $161.00 | -5.01% |
| ▲ Q3 FY2024 | Aug 13, 2024 | +1.7% | $197.05 | $197.05 | +0.00% |
| ▼ Q2 FY2024 | Apr 11, 2024 | -31.7% | $188.25 | $180.75 | -3.98% |
| ▼ Q2 FY2023 | Jun 30, 2023 | -51.1% | $187.30 | $187.30 | +0.00% |
| ▼ Q4 FY2022 | Dec 30, 2022 | -32.6% | $195.06 | $195.06 | +0.00% |
| ▼ Q2 FY2022 | Jun 30, 2022 | -42.3% | $184.25 | $184.00 | -0.14% |
Q1 FY2026+3.17%
Report Date
Feb 10, 2026
EPS Beat/Miss
-2.7%
Price Before
$121.74
Price After
$125.60
Q3 FY2025+6.33%
Report Date
Aug 18, 2025
EPS Beat/Miss
-47.3%
Price Before
$168.35
Price After
$179.00
Q1 FY2025-5.01%
Report Date
Feb 11, 2025
EPS Beat/Miss
-42.0%
Price Before
$169.50
Price After
$161.00
Q3 FY2024+0.00%
Report Date
Aug 13, 2024
EPS Beat/Miss
+1.7%
Price Before
$197.05
Price After
$197.05
Q2 FY2024-3.98%
Report Date
Apr 11, 2024
EPS Beat/Miss
-31.7%
Price Before
$188.25
Price After
$180.75
Q2 FY2023+0.00%
Report Date
Jun 30, 2023
EPS Beat/Miss
-51.1%
Price Before
$187.30
Price After
$187.30
Q4 FY2022+0.00%
Report Date
Dec 30, 2022
EPS Beat/Miss
-32.6%
Price Before
$195.06
Price After
$195.06
Q2 FY2022-0.14%
Report Date
Jun 30, 2022
EPS Beat/Miss
-42.3%
Price Before
$184.25
Price After
$184.00
Avg Beat Reaction+0.00%
Avg Miss Reaction+0.05%
Beat Rate1 / 8 quarters
Largest Move+6.33% (Q3 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CMXHF ends December
CSL Limited (CMXHF) most recently reported earnings on February 10, 2026 for Q1 FY2026, posting EPS of $4.03 — missing the analyst consensus of $4.14 by -2.7%. The next CMXHF earnings date is expected around September 1, 2026.
Each quarter, investors track CMXHF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CMXHF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CMXHF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CMXHF earnings · 5 questionsCSL Limited's next earnings report is expected around September 1, 2026. CMXHF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CMXHF historically reports after market close (AMC).
CMXHF earnings datewhen is CMXHF earningsCMXHF next earnings datewhen does CMXHF report earningsCMXHF earnings calendar
▸ Source: FMP · CSL Limited SEC filings · US GAAP · CSL Limited SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026